Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | RAB9A | P51151 | 2/20 | 0.43 |
| ▸ | GAA | P10253 | 1/20 | 0.43 |
| ▸ | ATM | Q13315 | 1/20 | 0.43 |
| ▸ | KDM4E | B2RXH2 | 5/20 | 0.42 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.42 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.41 |
| ▸ | HSD17B10 | Q99714 | 2/20 | 0.41 |
| ▸ | USP2 | O75604 | 1/20 | 0.41 |
| ▸ | PTGDR2 | Q9Y5Y4 | 4/20 | 0.40 |
| ▸ | MAPT | P10636 | 1/20 | 0.40 |
| ▸ | SYK | P43405 | 2/20 | 0.39 |
| ▸ | AKR1B1 | P15121 | 5/20 | 0.39 |
| ▸ | AKR1B10 | O60218 | 4/20 | 0.38 |
| ▸ | AKR1A1 | P14550 | 3/20 | 0.37 |
| ▸ | GLA | P06280 | 2/20 | 0.36 |
| ▸ | MEN1 | O00255 | 1/20 | 0.36 |
| ▸ | CASP1 | P29466 | 1/20 | 0.36 |
| ▸ | CASP7 | P55210 | 1/20 | 0.36 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.36 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1120430 | 0.86 | PTGDR2 (0.53) | RAB9AGAAATMKDM4EALDH1A1 | |
| SCHEMBL1120346 | 0.85 | AKR1B1 (0.51) | GAAKDM4EALDH1A1HSD17B10PTGDR2 | |
| SCHEMBL1120420 | 0.85 | NPC1 (0.43) | RAB9AKDM4EALDH1A1HSD17B10PTGDR2 | |
| SCHEMBL1120464 | 0.83 | PTGDR2 (0.39) | RAB9AGAAATMKDM4EALDH1A1 | |
| SCHEMBL1120373 | 0.81 | AKR1B1 (0.39) | RAB9AGAAATMKDM4EALDH1A1 | |
| SCHEMBL1120360 | 0.80 | RAB9A (0.45) | RAB9AGAAATMKDM4EALDH1A1 | |
| SCHEMBL1120427 | 0.80 | FABP4 (0.49) | RAB9AGAAATMKDM4EALDH1A1 | |
| SCHEMBL1120366 | 0.77 | RAB9A (0.42) | RAB9AGAAATMKDM4EALDH1A1 | |
| SCHEMBL1120444 | 0.76 | AKR1B1 (0.53) | KDM4EL3MBTL1HSD17B10PTGDR2AKR1B1 | |
| SCHEMBL1120370 | 0.73 | AKR1B1 (0.59) | RAB9AGAAATMKDM4EALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9469641-B2 | Pyrido[3,4-B]indoles and methods of use | MEDIVATION TECHNOLOGIES, INC. (US) | 2016-10-18 | — | — | US | disclosed |
| US-9260429-B2 | Pyrido[3,4-B]indoles and methods of use | MEDIVATION TECHNOLOGIES, INC. (US) | 2016-02-16 | — | — | US | disclosed |
| US-20130190323-A1 | PYRIDO[3,4-B]INDOLES AND METHODS OF USE | MEDIVATION TECHNOLOGIES, INC. (US) | 2013-07-25 | — | — | US | disclosed |
| US-20130184306-A1 | PYRIDO[3,4-B]INDOLES AND METHODS OF USE | MEDIVATION TECHNOLOGIES, INC. (US) | 2013-07-18 | — | — | US | disclosed |
| US-20130131077-A1 | PYRIDO[3,4-B]INDOLES AND METHODS OF USE | MEDIVATION TECHNOLOGIES, INC. (US) | 2013-05-23 | — | — | US | disclosed |
| US-20130079352-A1 | PYRIDO[3,4-B]INDOLES AND METHODS OF USE | MEDIVATION TECHNOLOGIES, INC. (US) | 2013-03-28 | — | — | US | disclosed |
| US-8338447-B2 | Pyrido[3,4-B]indoles and methods of use | MEDIVATION TECHNOLOGIES, INC. (US) | 2012-12-25 | — | — | US | disclosed |
| EP-2280968-A2 | PYRIDO [3, 4-B]INDOLES AND METHODS OF USE | Medivation Technologies, Inc. (US) | 2011-02-09 | — | — | EP | disclosed |
| US-20090270412-A1 | PYRIDO[3,4-B]INDOLES AND METHODS OF USE | MEDIVATION TECHNOLOGIES, INC. | 2009-10-29 | — | — | US | disclosed |
| WO-2009120717-A2 | PYRIDO [3, 4-B] INDOLES AND METHODS OF USE | MEDIVATION TECHNOLOGIES, INC. (US) | 2009-10-01 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130184306-A1 | PYRIDO[3,4-B]INDOLES AND METHODS OF USE | HTR3B, HTR4, HTR2C | RAB9A 1487/4885GAA 3526/4885ATM 4116/4885 |
| US-20130079352-A1 | PYRIDO[3,4-B]INDOLES AND METHODS OF USE | HTR3B, HTR4, HTR2C | RAB9A 1487/4885GAA 3526/4885ATM 4116/4885 |
| US-20090270412-A1 | PYRIDO[3,4-B]INDOLES AND METHODS OF USE | HTR3B, HTR4, HTR2C | RAB9A 1487/4885GAA 3526/4885ATM 4116/4885 |
| US-20130190323-A1 | PYRIDO[3,4-B]INDOLES AND METHODS OF USE | HTR3B, HTR4, HTR2C | RAB9A 1487/4885GAA 3526/4885ATM 4116/4885 |
| US-20130131077-A1 | PYRIDO[3,4-B]INDOLES AND METHODS OF USE | HTR3B, HTR2C, HTR4 | RAB9A 1346/4885GAA 3484/4885ATM 3929/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.